Laboratory M&A: A Shrinking Window of Opportunity
Mergers and acquisitions of laboratories during the first half of 2013 appear to be flat, with the number of transactions remaining about the same as compared to the first half of 2012. Altogether, seven deals were reported by two firms that monitor such transactions, England & Co. in Washington, D.C., and Haverford Healthcare Advisors in Paoli, Pa. According to Haverford, seven deals also occurred during the first half of 2012, suggesting a market that is stable if not dynamic. By comparison, 16 deals were consummated during the first half of 2011. Industry observers say that the environment for deal-making has been dampened by a variety of issues. Among them are reimbursement pressures, particularly regarding the technical component of CPT code 88305, the 2 percent across-the-board cuts to Medicare reimbursement as part of the budget sequester, reductions to the Part B lab fee schedule, and additional cuts to payments as a result of gap-filling new molecular pathology test codes in lieu of the older code-stacking payment methodology. “You have quite a few headwinds in the industry right now. Private equity-backed labs are taking a breather and many of the previous acquirers are no longer active,” said England & Co. Managing Director […]
M&A Activity, First Half of 2013 | |
Month Closed | Acquirer-Acquired |
January | Quest Diagnostics-UMass Memorial Medical Center |
January | Access Genetics-OralDNA |
January | Ascend Clinical-PathCentral |
January | Selah Genomics-Lab 21 Ltd. (SC) |
April | LabCorp-United West Laboratories (AZ) |
May | Quest Diagnostics-Concentra |
June | Quest Diagnostics-Dignity Health Lab Outreach (CA and NV) |
Sources: Haverford Healthcare Advisors, England & Co. |
Subscribe to view Essential
Start a Free Trial for immediate access to this article